Can donor immune cells fight leukemia relapse after transplant?

NCT ID NCT06641648

Recruiting now Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether infusing natural killer (NK) cells from a healthy donor, combined with low-dose interleukin-2 (IL-2), can safely help treat acute myeloid leukemia (AML) that has returned after a stem cell transplant. The study involves about 12 adults with AML relapse and aims to evaluate the safety, tolerability, and preliminary effectiveness of this approach. Participants will receive the donor NK cell infusion and IL-2, and researchers will monitor for side effects and signs of remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Donor natural killer (NK) cells combined with low-dose interleukin-2 (IL-2)
What this could lead to: If successful, this approach could offer a new treatment option for patients with AML that returns after a stem cell transplant, potentially improving remission rates.
What could go wrong: This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. There may be risks such as graft-versus-host disease or other treatment-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML) ACUTE MYELOID LEUKEMIA (AML) RELAPSE NK CELL

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.